234 related articles for article (PubMed ID: 27772740)
1. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
Gasperini C; Hupperts R; Lycke J; Short C; McNeill M; Zhong J; Mehta LR
J Neurol Sci; 2016 Nov; 370():123-131. PubMed ID: 27772740
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
[TBL] [Abstract][Full Text] [Related]
3. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Pavsic K; Pelicon K; Ledinek AH; Sega S
Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
[TBL] [Abstract][Full Text] [Related]
4. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of prolonged-release fampridine
Hupperts R; Gasperini C; Lycke J; Ziemssen T; Feys P; Xiao S; Acosta C; Koster T; Hobart J
Ther Adv Neurol Disord; 2022; 15():17562864221090398. PubMed ID: 35601756
[TBL] [Abstract][Full Text] [Related]
6. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
[TBL] [Abstract][Full Text] [Related]
7. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
[TBL] [Abstract][Full Text] [Related]
8. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
[TBL] [Abstract][Full Text] [Related]
9. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
10. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Keune PM; Cocks AJ; Young WR; Burschka JM; Hansen S; Hofstadt-van Oy U; Oschmann P; Muenssinger J
BMC Neurol; 2015 Sep; 15():171. PubMed ID: 26400041
[TBL] [Abstract][Full Text] [Related]
11. A guide to treating gait impairment with prolonged-release fampridine (Fampyra
Ramió-Torrentà L; Álvarez-Cermeño JC; Arroyo R; Casanova-Estruch B; Fernández O; García-Merino JA; Hernández MA; Izquierdo G; Martínez-Yélamos S; Meca J; Moral E; Olascoaga J; Prieto JM; Saiz A
Neurologia (Engl Ed); 2018 Jun; 33(5):327-337. PubMed ID: 26873645
[TBL] [Abstract][Full Text] [Related]
12. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Zörner B; Kapitza S; Reuter K; Lörincz L; Weller D; Sutter T; Killeen T; Gruber P; Petersen JA; Weller M; Linnebank M
Neurology; 2017 Feb; 88(9):832-841. PubMed ID: 28148629
[TBL] [Abstract][Full Text] [Related]
13. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
[TBL] [Abstract][Full Text] [Related]
14. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
[TBL] [Abstract][Full Text] [Related]
15. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
Morrow SA; Rosehart H; Johnson AM
Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
[TBL] [Abstract][Full Text] [Related]
16. Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study.
Castelnovo G; Gerlach O; Freedman MS; Bergmann A; Sinay V; Castillo-Triviño T; Kong G; Koster T; Williams H; Gafson AR; Killestein J
CNS Drugs; 2021 Sep; 35(9):1009-1022. PubMed ID: 34322853
[TBL] [Abstract][Full Text] [Related]
17. Proxy measurements in multiple sclerosis: agreement on different patient-reported outcome scales.
Sonder JM; Bosma LV; van der Linden FA; Knol DL; Polman CH; Uitdehaag BM
Mult Scler; 2012 Feb; 18(2):196-201. PubMed ID: 21908479
[TBL] [Abstract][Full Text] [Related]
18. Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability.
Kim ES
Drugs; 2017 Sep; 77(14):1593-1602. PubMed ID: 28864863
[TBL] [Abstract][Full Text] [Related]
19. Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis.
Valet M; Quoilin M; Lejeune T; Stoquart G; Van Pesch V; El Sankari S; Detrembleur C; Warlop T
CNS Drugs; 2019 Nov; 33(11):1087-1099. PubMed ID: 31612418
[TBL] [Abstract][Full Text] [Related]
20. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
Goodman AD; Cohen JA; Cross A; Vollmer T; Rizzo M; Cohen R; Marinucci L; Blight AR
Mult Scler; 2007 Apr; 13(3):357-68. PubMed ID: 17439905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]